Press Releases Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
13.51 ^USD	-3.15%		+5.71%	+30.91%

04-12	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT
04-12	Sector Update: Health Care	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference	05-07	AQ
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	04-16	AQ
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering	04-15	AQ
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering	04-12	AQ
Nurix Therapeutics Announces Proposed Public Offering	04-11	AQ
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update	04-10	AQ
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	04-09	AQ
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	04-09	AQ
Nurix Therapeutics to Participate in Upcoming Investor Conferences	04-03	AQ
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences	04-02	AQ
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)	03-25	AQ
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting	03-20	AQ
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial	03-11	AQ
Nurix Therapeutics to Participate in Upcoming Investor Conferences	03-06	AQ
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting	03-05	AQ
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update	02-15	AQ
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader	02-01	AQ
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL	01-16	AQ
Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases	01-08	AQ
Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference	01-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Press Releases

Filters